Epitopea develops off-the-shelf RNA immunotherapies that target aberrantly expressed tumor-specific antigens (aeTSAs) identified through its proprietary CryptoMap™ platform. This approach aims to enhance cancer treatment efficacy by providing durable benefits while minimizing side effects for patients with difficult-to-treat cancers.
Funding
$44.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer immunotherapies often struggle to effectively target tumor cells while minimizing off-target effects, leading to limited efficacy and significant side effects for patients with difficult-to-treat cancers. Identifying shared tumor-specific antigens that are truly specific and accessible to the immune system remains a significant challenge.
Solution
Epitopea is developing off-the-shelf RNA immunotherapies that target a novel class of aberrantly expressed tumor-specific antigens (aeTSAs), also known as Cryptigen™ TSAs. These antigens are shared across multiple patients with the same tumor type and are identified using the company's proprietary CryptoMap™ platform, which analyzes 'junk DNA' to reveal these hidden targets. By targeting these aeTSAs, Epitopea aims to enhance cancer treatment efficacy by providing durable benefits while minimizing off-target effects. The RNA immunotherapies are designed to be accessible and readily available for a broad range of patients.
Target Audience
The primary target audience includes patients with difficult-to-treat cancers who could benefit from more effective and less toxic immunotherapies, as well as the clinicians who treat them.
Features
- CryptoMap™ platform for identifying shared, aberrantly expressed tumor-specific antigens (aeTSAs) or Cryptigen™ TSAs
- Off-the-shelf RNA immunotherapies targeting Cryptigen™ TSAs
- Focus on difficult-to-treat cancers
- Designed for durable benefits and minimized side effects